PeptiDream Executive and Leadership Team

Kiichi Kubota, the President & Chief Executive Officer at PeptiDream, directs the company's overarching strategy and operational execution. Kubota guides the organization's mission to become a global leader in drug discovery and development, leveraging PeptiDream's proprietary Peptide Discovery Platform System (PDPS). This advanced platform enables the efficient production of highly diverse non-standard peptide libraries, crucial for identifying potent therapeutic candidates. The President & Chief Executive Officer ensures alignment with the company's commitment to addressing unmet medical needs and enhancing patient outcomes worldwide. Kubota's leadership focuses on driving innovation within the biopharmaceutical sector, fostering collaborations, and steering the company towards sustainable growth and market impact. The strategic direction set by Kiichi Kubota underpins PeptiDream's ambition to develop novel peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics.

Patrick Reid, the Chief Executive Officer & President at PeptiDream, spearheads the company's strategic vision and global expansion initiatives. Reid oversees the advancement of PeptiDream's proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art technology for generating diverse peptide libraries to identify high-potency drug candidates. The Chief Executive Officer & President drives the company's aspiration to lead in drug discovery and development, focusing on therapeutic solutions for conditions with unmet medical needs. Patrick Reid's leadership emphasizes operational excellence and the efficient translation of scientific breakthroughs into tangible patient benefits. This role involves fostering key partnerships and ensuring the company's biopharmaceutical innovations contribute significantly to improving global health outcomes. Reid's strategic oversight ensures PeptiDream remains at the forefront of therapeutic development, from peptide-based to small molecule and peptide-drug-conjugate modalities.

Kiyofumi Kaneshiro, the Chief Financial Officer at PeptiDream, manages the company's financial operations and strategic fiscal planning. Kaneshiro oversees all aspects of financial reporting, budgeting, and investment strategies, ensuring the fiscal health and sustainability of PeptiDream's drug discovery and development initiatives. The Chief Financial Officer plays a critical role in supporting the company's growth trajectory, particularly in relation to its proprietary Peptide Discovery Platform System (PDPS) and the development of novel therapeutics. Kiyofumi Kaneshiro ensures compliance with financial regulations and optimizes resource allocation to maximize the efficiency of research and development efforts. This leadership position is vital for securing funding, managing capital, and driving shareholder value as PeptiDream pursues its mission to address unmet medical needs globally. Kaneshiro's financial acumen supports the company's long-term objectives in biopharmaceutical innovation.

Keiichi Masuya, the Chief Operating Officer at PeptiDream, directs the company's day-to-day operational activities and process optimization. Masuya ensures the efficient functioning of PeptiDream's research and development operations, particularly concerning the proprietary Peptide Discovery Platform System (PDPS) and its application in generating diverse peptide libraries. The Chief Operating Officer oversees the implementation of strategies designed to accelerate the identification and development of potent therapeutic candidates. Keiichi Masuya focuses on enhancing operational efficiency, managing supply chains, and ensuring seamless integration of new technologies to support the company's mission of improving patient quality of life worldwide. This role is integral to translating scientific advancements into viable therapeutic products, including peptide-based, small molecule-based, and peptide-drug-conjugate-based treatments. Masuya's operational leadership drives the company's capacity to meet its development milestones and market objectives.